Human Genome Sciences HGSI Upgraded - $26 Price Target

August 4, 2009 - Shares of Human Genome Sciences Inc. (HGSI) should get a nice lift today after a huge upgrade out of Think Equity. The firm is raising assumptions on Lupus drug Benlysta and raising the price target from $18 to $26 per share.

HGSI stock is indicated to open pre market trading at $14.90, Up 5.27%

If you are not familiar with HGSI - read this news story from Reuters.

Human Genome lupus trial success is classic biotech


For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free